Waters Corp Guides 2026 Organic Revenue Growth of 7%-9%
WAT sits 33% above its 52-week low of $275.05.
Summary
Waters Corp issued strong 2026 organic constant-currency revenue growth guidance of 7%-9%, signaling confidence in its product pipeline and end-market demand. This positive outlook is further supported by sales boosted by a new unit and improvements in end markets. The company's growth trajectory is also expected to benefit from a series of recent product launches, including the Xevo MRT P10 mass spectrometer and the FDA-cleared BD BACTEC FXI system. This concrete top-line target, for a company with a market cap near $37 billion, is expected to shape investor expectations and valuation models, with sustained high-single-digit organic growth being a material positive for the stock. Management may provide additional color on the drivers behind this forecast during the Q2 2026 earnings report, which is the next catalyst.
At the time of this announcement, WAT was trading at $364.69 on NYSE in the Life Sciences sector, with a market capitalization of approximately $36.8B. The 52-week trading range was $275.05 to $414.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.